Biomaterials. 2019 Jun 26;217:119308. doi: 10.1016/j.biomaterials.2019.119308. [Epub ahead of print]
Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity.

Sanchez-Guzman D1, Le Guen P2, Villeret B1, Sola N1, Le Borgne R3, Guyard A4, Kemmel A1, Crestani B2, Sallenave JM1, Garcia-Verdugo I5.
Author information

Abstract

Most of current influenza virus vaccines fail to develop a strong immunity at lung mucosae (site of viral entry) due to sub-optimal vaccination protocols (e.g. inactivated virus administered by parenteral injections). Mucosal immunity could be improved by using locally-delivered vaccines containing appropriate adjuvants. Here we show, in a mouse model, that inclusion of silver nanoparticles (AgNPs) in virus-inactivated flu vaccine resulted in reduction of viral loads and prevention of excessive lung inflammation following influenza infection. Concomitantly, AgNPs enhanced specific IgA secreting plasma cells and antibodies titers, a hallmark of successful mucosal immunity. Moreover, vaccination in the presence of AgNPs but not with gold nanoparticles, protected mice from lethal flu. Compared with other commercial adjuvants (squalene/oil-based emulsion) or silver salts, AgNPs stimulated stronger antigen specific IgA production with lower toxicity by promoting bronchus-associated lymphoid tissue (BALT) neogenesis, and acted as a bona fide mucosal adjuvant.
Copyright 2019 Elsevier Ltd. All rights reserved.


KEYWORDS:

Adjuvant; Immunity; Influenza virus; Lung vaccination; Silver nanoparticles; Vaccine

PMID: 31279103 DOI: 10.1016/j.biomaterials.2019.119308